Kyverna Therapeutics faces investor allegations it omitted lupus trial data in IPO documents

Kyverna Therapeutics and the architects of its 2024 market debut face investor allegations that they omitted clinical trial data about a kidney-related lupus therapy in the biopharmaceutical company's IPO documents.

Detected & updated continuously · Source: Nebula